文献速递免疫规划妇幼与学校卫生

儿童肺炎球菌结合疫苗失败:文献系统综述

Pneumococcal conjugate vaccine failure in children: A systematic review of the literature.
PubMed 文献 · Vaccine · 2016-11-09

该系统综述检索2000年1月至2016年4月英文文献,纳入20篇出版物共7584名≤5岁儿童,评估接种PCV7、PCV10、PCV13后疫苗失败的程序、危险因素、血清型分布、临床表现和结局。共识别159例疫苗失败,占报告IPD病例的2.1%(95%CI 1.8-2.4%);主要血清型为19F(39.8%)、6B(25.8%)和4(7.8%),合并症比例较高(42.9%),粗病死率较低(2.4%)。

要点

  • 疫苗失败占报告IPD病例的2.1%(95%CI 1.8-2.4%),无论疫苗或程序如何均罕见。
  • 已知血清型的失败病例中19F占39.8%、6B占25.8%、4占7.8%。
  • 报告合并症的8项研究中33/77例(42.9%)有基础疾病,粗病死率2.4%(2/85)。

核心结论

  • 肺炎球菌结合疫苗失败罕见,与疫苗种类或接种程序无关,但已建立肺炎球菌疫苗接种规划的国家需更系统地报告疫苗失败病例。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE、Cochrane图书馆及已识别文章参考文献中2000年1月至2016年4月发表的英文文献。
  • 纳入20篇出版物,涉及7584名≤5岁儿童;10项研究5202名儿童(68.6%)接种2剂后加强,2项研究64名儿童(0.8%)接种3剂无加强,8项研究2318名儿童(30.6%)接种3+1程序。

主要发现

  • 共识别159例疫苗失败,占报告IPD病例的2.1%(95%CI 1.8-2.4%)。
  • 报告合并症的8项研究中,33/77例(42.9%)有基础疾病。
  • 已知血清型的128例中,19F为51例(39.8%)、6B为33例(25.8%)、4为10例(7.8%)。
  • 仅5项研究报告患者结局,粗病死率为2.4%(2/85;95%CI 0.3-8.5%)。

关键数值与推荐

  • 多数研究未报告临床特征或结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 多数研究未报告临床特征或结局。
  • 仅五项研究报告患者结局,粗病死率95%CI为0.3-8.5%。
  • 已建立肺炎球菌疫苗接种规划的国家需更系统地报告疫苗失败病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing pneumococcal invasive disease (IPD) due to serotypes included in the vaccines. The risk of vaccine-type IPD in immunised children (i.e. vaccine failure) has not been systematically assessed in countries with established PCV programmes. METHODS: We undertook a systematic review of the English literature published from January 2000 to April 2016 to evaluate the vaccine schedule, risk factors, serotype distribution, clinical presentation and outcomes of vaccine failure in children vaccinated with the 7-valent (PCV7), 10-valent (PCV10), and 13-valent (PCV13) vaccines. Data sources included MEDLINE, EMBASE, Cochrane library, and references within identified articles. RESULTS: We identified 1742 potential studies and included 20 publications involving 7584 participants in children aged ⩽5year-olds: 5202 received 2 doses followed by a booster in 10 studies, (68.6%), 64 (0.8%) received 3 doses without a booster in 2 studies, and 2318 received a 3+1 schedule (30.6%) in 8 studies. A total of 159 vaccine failure cases were identified, representing 2.1% [95% CI: 1.8-2.4%] of the reported IPD cases. Most studies did not report clinical characteristics or outcomes. Among eight studies reporting comorbidities, 33/77 patients (42.9%) had an underlying condition. The main serotypes associated with vaccine failure were 19F (51/128 cases with known serotype; 39.8%), 6B (33/128; 25.8%), and 4 (10/128; 7.8%). Only five studies reported patient outcomes, with a crude case fatality rate of 2.4% (2/85; 95%CI: 0.3-8.5%). CONCLUSION: Pneumococcal conjugate vaccines have been implemented in national immunisation programmes for more than a decade, yet there are only a few studies reporting vaccine failure. PCV failure is rare, irrespective of vaccine or schedule. Co-morbidity prevalence was high amongst vaccine failure cases but case fatality rate was relatively low. There is a need for more systematic reporting vaccine failure cases in countries with established pneumococcal vaccination programmes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Oligbu G, Hsia Y, Folgori L, et al. Pneumococcal conjugate vaccine failure in children: A systematic review of the literature. Vaccine. 2016. PMID: 27838066. doi:10.1016/j.vaccine.2016.10.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。